Our approach
The immune system plays multiple roles among which the detection and destruction of cancer cells. To escape immunosurveillance, tumors inactivate the immune system not only via direct contact through immune checkpoint system, but also by releasing immunosuppressive molecules in the tumor microenvironement. Such strategies lead to tumor escape and limited effects of immune checkpoint inhibitor based therapies.
We exploit a robust preclinical and clinical process to identify and validate GPCRs targets involved in immunosurveillance mechanisms.
Selected GPCRs are supported by a science-driven rationale, and we design and launch small molecule or monoclonal antibody discovery programs dedicated to deliver best-in-class and first-in-class candidates to the clinic.
GPCRs and Immuno-oncology
GPCRs constitute a large family of membrane receptors having delivered numbers of marketed drugs. Recently, some GPCRs have emerged as playing a strategic pivotal role in immunosuppression triggered by tumors to bypass immune system as well as to escape to immune checkpoint inhibitor treatments.
As an expert of GPCRs, Domain Therapeutics relentlessly dedicates its energy to discover and bring to cancer patients innovative GPCR targeting drugs addressing this important target family.